Santhera Shares Sink On Duchenne Setback in Europe

 
• By Kevin Grogan

Hopes were high for an expanded approval of Raxone but the CHMP's negative opinion has left the Swiss company's stock battered and bruised.

Red Arrow Loss_1200
Santhera stock on the slide after negative opinion from CHMP • Source: Shutterstock

More from Business

More from Scrip